Welcome to our dedicated page for Pulmatrix SEC filings (Ticker: PULM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Pulmatrix, Inc. filings document material events for a biopharmaceutical issuer developing inhaled therapeutic candidates through its iSPERSE platform. The record includes Form 8-K disclosures on operating and financial results, corporate updates, clinical or regulatory matters, material agreements, shareholder voting matters, governance actions and capital-structure information.
These filings also capture Regulation FD communications and other event reports tied to Pulmatrix's public-company reporting obligations, including disclosures related to strategic transaction agreements and related governance matters.
Pulmatrix, Inc. reported a first-quarter 2026 net loss of $1.2 million, improved from a $1.8 million loss a year earlier, as operating expenses fell to $1.3 million with R&D largely paused and lower general and administrative costs.
Cash and cash equivalents were $3.3 million at March 31, 2026, plus $0.7 million of restricted cash, after raising $1.0 million via Series B Convertible Preferred Stock tied to its planned merger with Eos SENOLYTIX. Management states there is substantial doubt about the company’s ability to continue as a going concern if the Eos merger is not completed and notes the board may consider dissolution and liquidation in that case.
Under the merger terms, Eos stakeholders, including new financing investors, are expected to own about 94% of the combined company on a fully diluted basis, leaving current Pulmatrix stockholders with about 6%, while Pulmatrix’s pipeline of iSPERSE-based inhaled therapeutics remains on hold pending funding or strategic transactions.
Pulmatrix reported a Q1 2026 net loss of $1.2 million, compared with $1.8 million a year earlier, as operating expenses fell to $1.3 million from $1.8 million. Research and development spending was under $0.1 million as all clinical development is on hold while the company seeks to license or monetize its assets.
Cash and cash equivalents were $3.3 million as of March 31, 2026, down from $4.1 million at year-end. Management prepared the financials on a going-concern basis and expects available cash to fund operations at least through the anticipated closing of a proposed merger with Eos SENOLYTIX in the third quarter of 2026.
The company entered into a merger agreement with Eos and raised $1.0 million through a private placement of Series B Convertible Preferred Stock to an Eos affiliate. Existing Pulmatrix common shareholders are expected to own approximately 6% of the combined company, without dilution from the preferred stock.
RCM Eos PIPE HOLDINGS, LLC filed a Schedule 13D disclosing a significant investment in Pulmatrix, Inc. It purchased 1,000 shares of Series B Convertible Preferred Stock for $1,000,000, which are convertible into 405,358 Pulmatrix common shares, equal to 9.99% of the company’s common stock on an as-converted basis.
The preferred shares convert at roughly 454.55 common shares per preferred share at a $2.20 conversion price and carry 8% cumulative dividends payable in stock. This financing is tied to a planned merger in which Eos SENOLYTIX stockholders and related investors are expected to own about 94% of the combined company, leaving existing Pulmatrix stockholders with about 6% on a fully diluted basis.
Pulmatrix, Inc. closed a previously announced private placement of Series B Convertible Preferred Stock with an affiliate of Eos SENOLYTIX, Inc. as part of their planned merger process. The investment generated aggregate gross proceeds of approximately $1 million for Pulmatrix.
The Series B Preferred Stock is convertible into Pulmatrix common stock at a conversion price of $2.20 per share, beginning 90 days after the initial issuance date, and includes customary anti-dilution adjustments. Holders of the Series B Preferred Stock vote together with common stockholders as a single class. Pulmatrix currently intends to use the permitted net proceeds for working capital and other general corporate purposes.
Pulmatrix has signed a definitive agreement to merge with privately held Eos SENOLYTIX, a gerotherapeutics company targeting aging-related mitochondrial dysfunction. Pulmatrix will acquire Eos via a stock-for-stock merger, with Eos becoming a wholly owned subsidiary.
Based on the expected exchange ratio, pre‑Merger Eos stakeholders, including new financing investors and fee shares, are expected to own about 94% of the combined company on a fully diluted basis, while existing Pulmatrix stockholders will own about 6%. The combined entity will be renamed Eos SENOLYTIX, Inc. and is expected to trade on Nasdaq under the ticker "EOSX" if the transaction closes.
Alongside the Merger, Pulmatrix agreed to a $1 million private placement of Series B Convertible Preferred Stock at a stated value of $1,000 per share, convertible at $2.20 per share and carrying an 8% cumulative dividend payable in stock. These preferred shares vote with common stock and are subject to a 180‑day lock‑up and strong transfer restrictions.
Eos separately arranged an up to $18 million financing through convertible notes and equity, plus an additional planned Series A preferred round, to fund its MitoXcel™ platform and lead candidate PTC‑2105. The Merger and financings remain subject to stockholder approvals, Nasdaq listing approval, Form S‑4 effectiveness and other customary closing conditions.
Pulmatrix, Inc. and Eos SENOLYTIX, Inc. entered a definitive merger agreement under which Pulmatrix will acquire Eos and the combined company will operate as Eos SENOLYTIX, Inc. and is expected to trade on Nasdaq as EOSX. The transaction includes concurrent private financings totaling $19 million to support advancement of Eos’s MitoXcel™ platform and lead clinical candidate PTC-2105 for sarcopenia and sarcopenic obesity. The boards of both companies unanimously approved the Merger, which is expected to close in mid-2026, subject to customary closing conditions including stockholder approvals and effectiveness of a Form S-4 registration statement. Following closing and payment of placement and advisory fees, pre-Merger Pulmatrix stockholders are expected to own approximately 6% of the combined company and pre-Merger Eos stockholders are expected to own approximately 94%.
Pulmatrix, Inc. announced that Cullgen Inc. has terminated their previously agreed merger and all related transactions under the Merger Agreement. No termination fee will be paid by either party, and each will cover its own costs and expenses associated with the deal.
The merger, originally signed in November 2024 and approved by Pulmatrix stockholders in June 2025, had been awaiting approval from the China Securities Regulatory Commission, which was not obtained before Cullgen’s termination on February 28, 2026. Pulmatrix states that it continues to pursue alternative merger opportunities while highlighting its proprietary iSPERSE™ inhaled drug-delivery technology and clinical assets.
Pulmatrix, Inc. describes a company in transition that now depends heavily on a proposed merger with Cullgen to define its future. The Merger has been approved by Pulmatrix stockholders but still requires several closing conditions, including approval from China’s securities regulator, and may be delayed or terminated.
While awaiting completion, Pulmatrix has paused development of its iSPERSE™-based drug candidates PUR3100 for acute migraine, PUR1800 for COPD exacerbations, and PUR1900 for fungal lung disease, and is instead seeking ways to monetize these assets. Cipla has taken over most development and commercialization costs for PUR1900 outside the United States, where Pulmatrix would receive a 2% royalty on any potential future net sales.
The company emphasizes the strength of its inhaled dry powder iSPERSE™ platform and a large patent estate but reports only two full-time employees and minimal recent research spending. Management warns that if the Cullgen merger or other strategic transactions do not succeed, the board may consider dissolving and liquidating the company.
Pulmatrix, Inc. reported 2025 results showing a sharp shift to a leaner, pre‑revenue profile while pursuing a planned merger with Cullgen. Revenues fell to $0 for the year ended December 31, 2025, compared to $7.8 million in 2024, reflecting the wind down of the PUR1900 program and related Cipla agreement.
Research and development expenses dropped to about $0.1 million from $7.2 million, and general and administrative expenses declined to $5.1 million from $7.8 million, helping narrow the net loss to $5.2 million from $9.6 million. Cash and cash equivalents were $4.1 million at year-end 2025, down from $9.5 million, and the company anticipates this will fund operations into the first quarter of 2027.
The update highlights progress toward the proposed merger with Cullgen, which has been approved by Pulmatrix stockholders but remains subject to additional conditions, including Nasdaq listing approval and clearance from the China Securities Regulatory Commission. Pulmatrix and Cullgen have waived the merger’s “No Solicitation” clause, allowing both to explore alternative transactions. Pulmatrix is also actively seeking to license or monetize its iSPERSE™ technology and three associated clinical programs, including a Phase 2‑ready acute migraine candidate.
Pulmatrix, Inc. reported that on December 17, 2025 it entered into a mutual waiver agreement with Cullgen Inc. and PLC Merger Sub, Inc. related to their existing Merger Agreement. The waiver allows all parties to forego compliance with Section 5.4 of the Merger Agreement, which had imposed certain restrictions on each party during the pre-closing period. The company stated that, aside from this specific waiver, the Merger Agreement remains in full force and effect and no other terms have been amended, waived, or modified. Pulmatrix also issued a press release on December 18, 2025 describing the waiver, which is furnished as an exhibit.